USPTO Issues Sanctions Against Trademark Filing Entities (TFEs) for Fraudulent Filings

ethics trademark

On January 25, 2022, the United States Patent and Trademark Office issued sanctions against a group of trademark filing entities (“TFEs”): Abtach, Ltd., 360 Digital Marketing LLC, and Retrocube LLC, including the officers – Azneem Bilwani, CEO, Salman Yousuf, COO, Muhammad Saad Iqbal, President of Abtach, and Irsa Faruqui, President of Retrocube (collectively “Abtach TFEs”).  …

Continue Reading

Fed Circuit Watch: Nexus Required Between Attorney Fees Award and Misconduct

ethics fed circuit watch fees inequitable conduct patent

Another recently unsealed opinion from August 15, 2018 revealed a decision of the Court of Appeals for the Federal Circuit involving inequitable conduct and fee award.  In the opinion dated July 28, 2018, in In re Rembrandt Techs., LP Patent Litigation,[1] the Fed Circuit held that while the district court did not abuse its discretion, …

Continue Reading

IP Practicum: USPTO Proposes Patent Fee Increases for FY2019

ethics fees IP Practicum patent

On July 25, 2018, the USPTO submitted for publication a Federal Official Gazette notice of public hearing 2018-16432 pursuant to the Patent Public Advisory Committee (PPAC).  The notice specifies broad increases affecting patent filings and prosecution.  It was published on August 8, 2018, in the Federal Gazette. While most of the fees are in the …

Continue Reading

Fed Circuit Watch: Merck’s Unclean Hands Render Hep C Patents Unenforceable

ethics fed circuit watch inequitable conduct patent unclean hands

The doctrine of unclean hands is a judicially-created equitable defense in which equitable relief is denied where that party has acted in a fraudulent manner or in bad faith.[1]  Gilead Scis., Inc. v. Merck & Co., Inc.,[2] decided by the Court of Appeals for the Federal Circuit on April 25, 2018, discusses the confluence of …

Continue Reading

Fed Circuit Watch: Regeneron Denied Redemption in Misconduct Case

ethics fed circuit watch patent trials

On December 26, 2017, the Court of Appeals for the Federal Circuit denied a request for rehearing en banc for reconsideration made by Regeneron Pharmaceuticals, Inc., in a precedential decision.  This petition was filed following the original decision affirming specific intent litigation misconduct held in the original appellate case.  Judges Prost, Lourie, Dyk, Moore, O’Malley, …

Continue Reading

Fed Circuit Watch: Litigation Misconduct and Inequitable Conduct

duty of disclosure ethics inequitable conduct patent patent agent

By Brent T. Yonehara On July 27, 2017, the Court of Appeals for the Federal Circuit decided Regeneron Pharmaceuticals, Inc. v. Merus B.V.  In Regeneron, the Federal Circuit affirmed a district court’s finding that Regeneron’s patent 8,502,018 was unenforceable due to inequitable conduct.[1]  This case brings up the Therasense New Order of Inequitable Conduct in …

Continue Reading